Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by Amundi

Amundi lifted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 42.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,871 shares of the medical device company’s stock after buying an additional 20,970 shares during the period. Amundi owned approximately 0.11% of Tandem Diabetes Care worth $2,619,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Assetmark Inc. acquired a new position in Tandem Diabetes Care during the third quarter valued at $29,000. Crossmark Global Holdings Inc. acquired a new position in Tandem Diabetes Care during the third quarter valued at $200,000. State of New Jersey Common Pension Fund D lifted its position in Tandem Diabetes Care by 24.6% during the third quarter. State of New Jersey Common Pension Fund D now owns 44,776 shares of the medical device company’s stock valued at $1,899,000 after purchasing an additional 8,837 shares during the period. Los Angeles Capital Management LLC acquired a new position in Tandem Diabetes Care during the third quarter valued at $263,000. Finally, Victory Capital Management Inc. lifted its position in Tandem Diabetes Care by 45.6% during the third quarter. Victory Capital Management Inc. now owns 587,247 shares of the medical device company’s stock valued at $24,905,000 after purchasing an additional 183,877 shares during the period.

Tandem Diabetes Care Stock Performance

Shares of TNDM stock opened at $19.17 on Monday. The firm’s 50 day moving average price is $31.38 and its 200-day moving average price is $34.55. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. Tandem Diabetes Care, Inc. has a one year low of $17.64 and a one year high of $53.69. The firm has a market cap of $1.27 billion, a P/E ratio of -9.93 and a beta of 1.45.

Analyst Upgrades and Downgrades

TNDM has been the subject of a number of recent analyst reports. Barclays cut their price objective on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a report on Friday, February 28th. The Goldman Sachs Group cut their price objective on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $22.00 price objective (down previously from $38.00) on shares of Tandem Diabetes Care in a report on Monday, March 3rd. Royal Bank of Canada cut their price objective on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. Finally, Citigroup cut shares of Tandem Diabetes Care from a “buy” rating to a “neutral” rating and cut their price objective for the company from $35.00 to $24.00 in a report on Tuesday, March 4th. Eight research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, Tandem Diabetes Care presently has an average rating of “Moderate Buy” and an average target price of $45.38.

Insider Buying and Selling

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos bought 10,538 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average cost of $18.12 per share, with a total value of $190,948.56. Following the purchase, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.20% of the stock is owned by insiders.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.